Avastin/Lucentis Update 43: Secret Rebates Offered for Lucentis

First, Genentech refused to provide Lucentis for the CATT Study [...]; then they threatened to stop supplying Avastin to compounding pharmacies [...]; then they decided to provide Lucentis free of charge for the study looking at the use of panretinal laser treatment plus anti-VEGF (Lucentis) in the treatment of diabetic macular edema [...]; and now, the company is offering secret rebates to selected large users of Lucentis – obviously to blunt the potential expected to be offered by Avastin when the CATT Study results are released next Spring.

Full Story →